



# Non-Alcoholic Fatty Liver Disease in Children and Adolescents: Lifestyle Change - a Systematic Review and Meta-Analysis

Melina Utz-Melere,\* Cristina Targa-Ferreira,\*<sup>†</sup> Bernardo Lessa-Horta,<sup>‡</sup> Matias Epifanio,\*<sup>§</sup> Marialena Mouzaki,<sup>||</sup> Angelo A. Mattos<sup>¶</sup>

\* Santo Antônio Hospital, Santa Casa de Misericórdia Complex of Porto Alegre/RS, Brazil.

<sup>†</sup> Federal University of Health Sciences of Porto Alegre (UFCSPA), Brazil.

<sup>‡</sup> Federal University of Pelotas. Senior Researcher. FAPEAM, Brazil.

<sup>§</sup> Pontifical Catholic University of Rio Grande do Sul (PUCRS), Brazil.

<sup>||</sup> Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.

<sup>¶</sup> Federal University of Health Sciences of Porto Alegre (UFCSPA), Brazil.

## ABSTRACT

**Introduction and aim.** This manuscript seeks to analyze the impact of lifestyle changes on body mass index (BMI), aminotransferases and steatosis in children and adolescents with nonalcoholic fatty liver disease (NAFLD). **Material and methods.** A review of PubMed, BIREME, Scopus, EMBASE, Medline and Web of Science databases 2015 was performed seeking studies addressing the impact of lifestyle interventions on children and/or adolescents with NAFLD. Inclusion were manuscripts written in Portuguese, English and Spanish, as well as age less than 18 years. Two reviewers performed the data extraction independently and differences were resolved by consensus. Outcome measures were BMI, serum aminotransferase levels and the presence of hepatic steatosis. **Results.** The literature search identified 71,012 articles. After excluding 46,397 duplicates and other clearly irrelevant studies, 89 publications were reviewed in detail. Another 55 studies were excluded at this stage. Subsequently, 18 were excluded due to lack of data and three new articles were found in the review of the references of previously identified manuscripts. Therefore, 19 studies that had evaluated 923 subjects (477 boys and 446 girls) aged 6-18 years were included in the review. In most studies, the intervention included aerobic exercise and diet. In nine studies, BMI improved significantly following the intervention. The vast majority of studies reported a benefit from the intervention on aminotransferase levels. Lifestyle changes also had a significant impact on steatosis, reducing the risk by 61%. **Conclusion.** In conclusion lifestyle changes lead to significant improvements in BMI, aminotransferase levels and hepatic steatosis in children and adolescents with NAFLD.

**Key words.** Pediatric. Hepatic steatosis. Physical activity. Nutritional intervention. Obesity.

## INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is an increasingly common cause of chronic liver disease in children and adolescents,<sup>1</sup> likely due to an increase in the incidence of overweight and obesity in this population.<sup>2,3</sup> In Europe, the prevalence of overweight and obesity in children surpasses 30% and has been steadily increasing over the past decades.<sup>3</sup> In the United States, 16.9% of children aged 2 to 19 are obese.<sup>4</sup> In Brazil, more than 30% of children between the ages of 5 and 9 are overweight, while the prevalence of obesity is about 15%.<sup>5</sup>

NAFLD is classified histologically as either simple hepatic steatosis or non - alcoholic steatohepatitis (NASH), the latter being defined by hepatocellular steatosis and inflammation with or without fibrosis.<sup>6</sup> The gold standard for the diagnosis of NAFLD is histology obtained using liver biopsy, which can determine the presence of steatosis, inflammation or fibrosis.<sup>2</sup> The biopsy has some limitations; therefore, indirect methods have been used for diagnosis.<sup>7-10</sup>

NASH patients are more likely to develop progressive liver disease, such as cirrhosis and hepatocellular carcinoma, and have increased risk of developing cardiovascular

events.<sup>11-14</sup> The long-term prognosis of children with NAFLD remains unclear;<sup>12</sup> however, in adulthood these patients have a 14-fold increased risk of dying or requiring liver transplantation compared to the general population of the same age and sex.<sup>15</sup>

Due to the correlation of NAFLD with excess weight, the first step in treatment has traditionally been targeting obesity by stimulating lifestyle changes through physical activity and consumption of a healthier diet, as this is the only available treatment for these patients.<sup>16-18</sup> The number of well-designed, randomized controlled trials that have investigated the impact of lifestyle changes as a first-step intervention to treat pediatric NAFLD is small. Most intervention studies that combine diet and increased physical activity shows a benefit in NAFLD. Exercise, even without weight loss, appears to reduce steatosis, but the intensity of the exercise for the treatment of NAFLD has not yet been established. Isolated exercise, without caloric restriction, is not yet a proven strategy for the management of children with NAFLD.<sup>19-23</sup>

The aim of this study was to perform a systematic review and meta-analysis to assess the evidence on the impact of lifestyle interventions through aerobic exercise and a balanced diet on body mass index (BMI), serum aminotransferase levels and hepatic steatosis in children and adolescents NAFLD.

## MATERIAL AND METHODS

### Type of studies assessed

The search included randomized controlled trials, cohort, case-control studies, non-randomized controlled trials and non-controlled trials. Case reports, reviews, editorials and thesis dissertations were excluded. We included manuscripts published in Portuguese, English or Spanish.

### Types of exposure and participants

The trials included had investigated some form of lifestyle intervention, such as regular physical activity, diet or a combination of the two. Randomized trials that had investigated medications for the treatment of NAFLD were included but only data from the control arm were included in the analyses. Studies were included if variables BMI, aminotransferases and hepatic steatosis were available before and after the intervention.

Studies including participants under 18 years of age were included. In cases of combined adult and pediatric cohorts, data from individuals under the age of 18 years were included. All participants had to have a diagnosis of NAFLD for inclusion in the analysis. The diagnosis could

have been made clinically (overweight/obesity patient with abnormal aminotransferases or increased insulin resistance), radiologically (magnetic resonance imaging of the abdominal (MRI)), ultrasound or histologically following a liver biopsy.<sup>24,25</sup>

We excluded studies that evaluated children and adolescents with other chronic liver diseases such as infectious hepatitis, endocrinological diseases that could predispose to liver disease, steatosis secondary to parenteral nutrition, drugs or alcohol and studies that had evaluated the patients after surgery.

### Types of outcome measures

Studies were included if the outcome measures of interest were improvement in BMI, serum aminotransferase levels, as well as radiological or histological evidence of steatosis improvement. To compare BMI between ages and gender Z scores were used. A BMI between 85 and 96 percentiles for age was used to define overweight and percentile  $\geq 97$  was used as cut off for obesity.<sup>1,26</sup> Aminotransferases (ALT, AST) were used as the only laboratory test; the values were defined according to the laboratory reference of each study.<sup>16</sup>

### Search methods and selection of studies

PubMed, BIREME, Scopus EMBASE, Medline and Web of Science were reviewed by a single researcher. The search in the database covered articles published throughout the indexing period up to April 2015.

The literature search used the following key words: disease (hepatic steatosis non-alcoholic, non-alcoholic steatohepatitis, NAFLD, NASH, obesity, aminotransferase, aspartate aminotransferase AST, ALT, alanine aminotransferase, fatty liver and hepatic steatosis). These words were combined with the use of the following words: lifestyle intervention, physical activity, physical fitness, aerobic exercise, weight loss, intervention, treatment, nutritional intervention and diet.

Two reviewers (MUM and CTF) performed the data extraction independently and differences were resolved by consensus. Outcome measures were: BMI, serum levels of ALT and AST and the presence of hepatic steatosis, before and after the intervention. In each study data on participant's characteristics, such as gender, age and the way in which the intervention was performed were extracted. In cases of missing data, the corresponding author was contacted via email twice.

The effects of quantitative parameters were estimated using the patterned effect. For categorical parameters, we used the relative risk. For both effective measures, we cal-




Figure 1. Flow chart of meta-analysis inclusion.

culated intervals of 95% confidence. Q test was used to assess for heterogeneity of the studies and in the case of heterogeneity being greater than expected, we used the random effects model to obtain aggregated measurements. The significance level was 5% and the analysis were performed in STATA version 13.0.

## RESULTS

Following the initial search 71,012 articles were identified (Figure 1). After excluding 46,397 duplicates, 24,615 articles were reviewed and 24,333 were excluded. The abstracts of the 282 remaining manuscripts were reviewed, which led to the removal of another 193 studies. Eighty-nine manuscripts were read in their entirety leading to the exclusion of another 55 studies. Of the remaining 34 manuscripts 18 were not included, as they did not contain data necessary for the meta-analysis. Three more studies identified by reviewing the references of already included studies were selected as well. In total, 19 manuscripts (923 individuals) were selected for review and meta-analysis.

Out of the selected studies eight were controlled trials, three were nonrandomized and eight were non-controlled clinical trials. In most studies, the intervention included aerobic exercise and diet. In two studies<sup>27,28</sup> physical activity through aerobic exercise was the only intervention. The age of participants ranged from 6 to 18 years, and 477 were male and 446 females (Table 1).

The diet suggested was normocaloric ranging from 1.300-1900 Kcal/day with a caloric distribution as follows:

Table 1. Characteristics of the evaluated population.

| References                              | Location  | N*  | Age (SD)**    | Male (%) | BMI (SD)***      |
|---|-----------|-----|---------------|----------|------------------|
| Van der Heijden GJ (2010) <sup>27</sup> | EUA       | 15  | 12.6 (±0.4)   | 47%      | 33.7 (±1.1)      |
| Farris JW (2011) <sup>33</sup>          | EUA       | 23  | 6-12          | 22%      | 30.3 (± 4.56)    |
| Verduci E (2013) <sup>37</sup>          | Italy     | 46  | 6-14          | 46%      | 2.3 (± 0.4)****  |
| Gronbaek H (2012) <sup>16</sup>         | Denmark   | 117 | 12.1 (±1.3)   | 44%      | 28.0 (± 3.6)     |
| Antunes BDMM (2013) <sup>28</sup>       | Brazil    | 34  | 13.7 (± 1.17) | 65%      | 29.5 (± 5.1)     |
| Togashi K (2010) <sup>45</sup>          | Japan     | 33  | 10.1 (± 1.7)  | 70%      | 25.9             |
| Wang CL (2008) <sup>20</sup>            | China     | 19  | 13.4 (± 2.5)  | 68%      | 29.6 (±1.48)     |
| Nobili V (2006) <sup>1</sup>            | Italy     | 43  | 12.4 (± 3.02) | 30%      | 25.5 (± 3.6)     |
| Tazawa Y (1997) <sup>29</sup>           | Japan     | 73  | 10            | 95%      | 28.4             |
| Vajro P (2000) <sup>36</sup>            | Italy     | 11  | 8.5 (± 2.8)   | 55%      | n/d              |
| Tock L (2010) <sup>30</sup>             | Brazil    | 14  | 15-18         | 100%     | 37.0 (± 3.15)    |
| Nobili V (2006) <sup>39</sup>           | Italy     | 84  | 3-18.8        | 70%      | 25.9 (± 3.6)     |
| Tock L (2006) <sup>31</sup>             | Brazil    | 73  | 17 (± 1.6)    | 33%      | 36.5 (± 2.86)    |
| Reinehr T (2009) <sup>34</sup>          | London    | 109 | 6-16          | 53%      | 2.5 (± 0.04)**** |
| Pozzato C (2010) <sup>38</sup>          | Italy     | 26  | 6-14          | 42%      | 2.3 (± 0.46)**** |
| Santomauro M (2012) <sup>19</sup>       | Venezuela | 24  | 7-18          | 50%      | 28.3 (± 4.23)    |
| Akcam M (2011) <sup>35</sup>            | Turkey    | 22  | 11.3 (± 2.6)  | 45%      | 26.8 (± 4.0)     |
| Nadeau KJ (2009) <sup>32</sup>          | USA       | 13  | 15.1          | 38%      | 40.2 (± 1.8)     |
| Koot BG (2011) <sup>22</sup>            | Holland   | 144 | 14.1 (± 2.3)  | 38%      | 3.4 (± 0.40)**** |

\* N: Number of evaluated individuals. \*\* Age in years, informed as average. In the studies where it is not given, the data is informed as max and minimum age. SD: Standard deviation. \*\*\* BMI: Body Mass Index. SD: Standard Deviation. \*\*\*\* Values referent to weight/height Z score. n/d: unavailable.

50-65% from carbohydrates, 10-30% from fat and 12-20% from protein. In some studies, depending on the patient's age, 10 g of fiber were added to the diet. The details of the diet were not reported in seven studies.<sup>19,22,29-33</sup> Regarding physical activity, all studies assessed aerobic exercise, ranging from once a week to daily workouts of 60 minutes on average. The duration of intervention ranged between 4 and 52 weeks. Details of interventions are shown in table 2.

In most studies, hepatic steatosis was assessed using abdominal ultrasound.<sup>16,19,20,22,28-32,34-36</sup> Three studies assessed steatosis through MRI/MR spectroscopy<sup>27,37,38</sup> and only two studies included histological data as a means of assessing steatosis severity.<sup>1,39</sup>

With regards to the effect of intervention on BMI, figure 2 shows that in eight studies the result was not significant and in nine studies there was a decrease in BMI z-score. As the heterogeneity between studies was high ( $p < 0.001$ ), we used a random effects model to combine the studies and the standardized aggregate was -0.82 (95% CI: -1.26 to -0.37).

Figure 3 shows that in most studies there was a benefit from the intervention on ALT levels. The combined effect of using a random model was -1.35 (95% CI: -1.92 to -0.78), since the heterogeneity was increased ( $p < 0.001$ ). In five studies, intervention showed no effect on AST levels. However, in eight studies there was a significant drop in AST. The combined effect was -1.00 standard deviation (95% CI: -1.59 to -0.40) (Figure 4).

In figure 5, we note that the intervention was beneficial for hepatic steatosis in ten studies; but four studies showed no significant effect. The heterogeneity was high ( $p < 0.001$ ) and the pooled effect was estimated using random - effects model. The risk of steatosis reduced by 61% after the intervention (RR grouped = 0.39; 95% CI: 0.27 to 0.56).

## DISCUSSION

NAFLD is the most prevalent pediatric liver disease in the world and has become a serious health problem, as well as a challenge for pediatricians who aim at treating but also preventing the evolution of this condition. Adult studies suggest that lifestyle changes can be beneficial for the treatment of NAFLD.<sup>10,25</sup> The pediatric literature is characterized by small numbers of patients and heterogeneous interventions. This systematic review and meta-analysis shows that a balanced diet coupled with physical activity, improves BMI, aminotransferases and hepatic steatosis of children and adolescents with NAFLD, independent of puberty.<sup>19,35</sup>

Most patients with NAFLD are asymptomatic. NAFLD should be suspected in overweight / obese chil-

dren and adolescents if their waist circumference is  $> >$  95th percentile for age and sex.<sup>30</sup>

The outcome measures of this systematic review included changes in BMI and aminotransferase levels, as this is how patients are typically monitored in the clinical setting and these are the markers most often measured in pediatric interventional studies in the field of NAFLD. While they have both been found to correlate with disease severity, their sensitivity and specificity in determining steatosis is poor. BMI does not reflect body composition, and performs worse than waist circumference in predicting metabolic dysregulation, the hepatic manifestation of which is NAFLD.<sup>40</sup> It has also been shown to miss over a quarter of children with excess adiposity.<sup>41</sup> Aminotransferases have been shown to be inaccurate markers of steatosis when used for screening of NAFLD; ALT elevation above twice the upper limit of normal has a sensitivity 57% and specificity of 71% in this context.<sup>42</sup>

Magnetic resonance spectroscopy seems to be an imaging method quite promising, however, it still needs more studies.<sup>32</sup>

Given the invasive nature of liver biopsies, imaging is often used as an additional surrogate marker of steatosis. The available literature included in this systematic review reports predominantly on ultrasound-based estimates of hepatic steatosis. This is a significant limitation, as the positive predictive value of ultrasonography for the determination of steatosis ranges between 47-62%.<sup>43</sup> Only a limited number of studies included the use of MRI, which albeit better than ultrasonography,<sup>43</sup> its accuracy in pediatrics remains to be determined. An even fewer number of studies reported on the results of histology, which is considered the gold standard for the determination and quantification of hepatic steatosis in the context of NAFLD. The paucity of histological data also prevented the assessment of the impact of lifestyle interventions on hepatic fibrosis, which is the major determinant of long-term outcomes.<sup>44</sup>


The goal of treatment is the regression of steatosis/inflammation and/or liver fibrosis. The decrease in ALT is commonly used as a marker of improvement for NAFLD.<sup>1</sup>

Most studies included in this systematic review and meta-analysis assessed the impact of both dietary and physical activity interventions. The study of Van der Heijden, *et al.*<sup>27</sup> however, solely examined the impact of physical activity on the hepatic steatosis of adolescents. The results showed a significant reduction in hepatic steatosis mirrored by ALT changes, however, BMI z-scores did not change. The latter may be the result of the aforementioned limitations of BMI as a surrogate marker of obesity. Likewise, Ali, *et al.*<sup>28</sup> assessed the impact of physical activity, which resulted in a non-significant reduction of BMI.


**Table 2.** Details of the interventions used in each study for lifestyle change.

| References                              | Type of Intervention | Weekly frequency | Time of exercise (min) | Weeks of intervention | Nutrition  |
|---|----------------------|------------------|------------------------|-----------------------|--|
| Van der Heijden GJ (2010) <sup>27</sup> | Exercise             | 4x               | 30                     | 12                    | n/a  |
| Farris JW (2011) <sup>33</sup>          | Exercise and diet    | 3x               | 60                     | 12                    | n/d  |
| Verduci E (2013) <sup>37</sup>          | Exercise and diet    | 7x               | 30-45                  | 12                    | 55% carbohydrate<br>25% fat<br>12% protein                         |
| Gronbaek H (2012) <sup>16</sup>         | Exercise and diet    | 7x               | 60                     | 10                    | 60% carbohydrate<br>24% fat<br>16% protein<br>1,547Kcal/day        |
| Antunes BDMM (2013) <sup>28</sup>       | Exercise             | 3x               | 60                     | 20                    | n/a  |
| Togashi K (2010) <sup>45</sup>          | Exercise and diet    | 7x               | 60                     | 12                    | 55% carbohydrate<br>25% fat<br>20% protein<br>1,400-1,900Kcal/day  |
| Wang CL (2008) <sup>20</sup>            | Exercise and diet    | 3x               | 30                     | 4                     | 50% carbohydrate<br>10% fat<br>20% protein<br>1,300-1,600Kcal/day  |
| Nobili V (2006) <sup>1</sup>            | Exercise and diet    | 7x               | 45                     | 52                    | 50-60% carbohydrate<br>23-30% fat<br>15-20% protein<br>25-30cal/kg |
| Tazawa Y (1997) <sup>29</sup>           | Exercise and diet    | n/d              | n/d                    | 12                    | n/d  |
| Vajro P (2000) <sup>36</sup>            | Exercise and diet    | n/d              | n/d                    | 26                    | 65% carbohydrate<br>23% fat<br>12% protein<br>30cal/kg             |
| Tock L (2010) <sup>30</sup>             | Exercise and diet    | 3x               | 60                     | 52                    | n/d  |
| Nobili V (2006) <sup>39</sup>           | Exercise and diet    | 3x               | 45                     | 52                    | 50-60% carbohydrate<br>23-30% fat<br>15-20% protein<br>25-30cal/kg |
| Tock L (2006) <sup>31</sup>             | Exercise and diet    | 2x               | 60                     | 52                    | n/d  |
| Reinehr T (2009) <sup>34</sup>          | Exercise and diet    | 1x               | n/d                    | 52                    | 55% carbohydrate<br>30% fat<br>15-20% protein                      |
| Pozzato C (2010) <sup>38</sup>          | Exercise and diet    | 7x               | 45                     | 52                    | n/d<br>55-60% carbohydrate<br>25-30% fat<br>12-15% protein         |
| Santomauro M (2012) <sup>19</sup>       | Exercise and diet    | 3x               | 30                     | 52                    | n/d  |
| Akcam M (2011) <sup>35</sup>            | Exercise and diet    | 7x               | 30                     | 26                    | 50% carbohydrate<br>30% fat<br>20% protein<br>30cal/kg             |
| Nadeau KJ (2009) <sup>32</sup>          | Exercise and diet    | n/d              | n/d                    | 26                    | n/d  |
| Koot BG (2011) <sup>22</sup>            | Exercise and diet    | 3x               | 60                     | 26                    | n/d  |


n/a: not evaluated n/d: n/d: unavailable.




**Figure 2.** Combined effect of intervention over BMI.



**Figure 3.** Combined effect of the intervention on ALT levels.



**Figure 4.** Combined effect on AST levels.



**Figure 5.** Combined effect of intervention in the presence of hepatic steatosis.



In the study of Farris, *et al.*,<sup>33</sup> the intervention was performed in adolescents with physical activity associated to nutritional education. The results showed a statistically significant reduction in BMI and ALT levels. Similar results were found by Verduci, *et al.*,<sup>37</sup> which also showed a significant reduction in steatosis.

Pozzato, *et al.*<sup>38</sup> and Togashi, *et al.*<sup>45</sup> observed a significant decrease in BMI, but it was not significant in reducing aminotransferases. In some studies, the authors tried to estimate how much weight reduction was needed for a significant result in the improvement of NAFLD to occur. These values ranged from 1 to 10% weight loss to obtain some benefit.<sup>29,31,34,39</sup>

Due to the association of this disease with overweight, the first step in the treatment has been to prevent obesity, stimulating lifestyle change through physical activity and a healthier diet.<sup>16-18</sup> Physical exercise, even without weight loss, appears to decrease steatosis. Isolated exercise, without a calorie restriction, has not yet proven effective.<sup>19,22,23</sup>

In general, the studies seem to show that the decrease in weight is an important factor in reducing NAFLD markers. Even showing weight reduction variable values, there is a positive interference in the disease. The change in lifestyle seems, thus, to represent the first step in treating children and adolescents with NAFLD.

Lifestyle change with a healthier diet, gradual weight loss and increased physical activity seem to be the only effective treatment for this disease at present.<sup>6-14</sup>

This study has some limitations, such as the age of subjects, ranging from 6 to 18 years, justifying different pubertal stages of Tanner (pre-pubertal, pubertal and post-pubertal) and there may be some hormonal influence, although in many studies, this difference did not influence the results.<sup>19,37</sup> The gold standard in the diagnosis of NAFLD is a liver biopsy, but it is difficult to carry out obese children considered “healthy” and without a proven effective treatment plan to justify the procedure. Thus, the vast majority of studies conducted diagnosis by abdominal ultrasonography, this being a standard that is operator - dependent. Some of the studies were not randomized and some had no control group. None of the studies reported on long-term outcomes, specifically on what happens after lifestyle interventions are stopped. This is a key gap in the literature as NAFLD is a chronic condition with a constant impact on metabolic health. Finally, physical activity with respect to the time, intensity and duration differed between the included studies.

According to this systematic review and meta-analysis, lifestyle changes lead to improvement of NAFLD determined primarily via surrogate markers, even in patients who do not exhibit a significant weight reduction. More randomized controlled trials are needed to assess the im-

pact of lifestyle changes on the histology of patients with NAFLD.

## ABBREVIATIONS

- **ALT:** alanine aminotransferase.
- **AST:** aspartate aminotransferase.
- **BMI:** body mass index.
- **MRI:** magnetic resonance imaging.
- **MRI:** magnetic resonance imaging of the abdominal.
- **MRS:** magnetic resonance spectroscopy.
- **NAFLD:** nonalcoholic fatty liver disease.
- **NASH:** steatosis or non - alcoholic steatohepatitis.

## REFERENCES

1. Nobili V, Manco M, Devito R, Ciampalini P, Piemonte F, Marcellini M. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2006; 24: 1553-61.
2. Corte CD, Alisi A, Saccari A, De Vito R, Vania A, Nobili V. Nonalcoholic fatty liver in children and adolescents: an overview. *J Adolesc Health* 2012; 51: 305-12.
3. Rodriguez G, Gallego S, Breidenassel C, Moreno LA, Gottrand F. Is liver transaminases assessment an appropriate tool for the screening of non-alcoholic fatty liver disease in at risk obese children and adolescents? *Nutr Hosp* 2010; 25: 712-17.
4. Hsu E, Murray K. Is nonalcoholic fatty liver disease in children the same disease as in adults? *Clin Liver Dis* 2012; 16: 587-98.
5. Instituto Brasileiro de Geografia e Estatística (IBGE). Pesquisa de Orçamentos Familiares 2008-2009: antropometria e estado nutricional de crianças, adolescentes e adultos no Brasil. Rio de Janeiro: IBGE, 2011.
6. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology* 2012; 142: 1592-609.
7. Ued FV, Weffort VRS. Vitaminas antioxidantes no contexto da doença hepática gordurosa não alcoólica em crianças e adolescentes obesos. *Rev Paul Pediatr* 2013; 31: 523-30.
8. Alp H, Karaarslan S, Ekliloglu BS, Atabek ME, Altın H, Baysal T. Association between nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents. *Can J Cardiol* 2013; 29: 1118-25.
9. Ciba I, Widhalm K. The association between non-alcoholic fatty liver disease and insulin resistance in 20 obese children and adolescents. *Acta Paediatr* 2007; 96: 109-12.
10. Miriam MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, Mouzaki M, et al. NASPGHAN Clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children. *J Pediatr Gastroenterol Nutr* 2016; 64: 319-4.
11. Moran JR, Ghishan FK, Halter SA, Greene HL. Steatohepatitis in obese children: a cause of chronic liver dysfunction. *Am J Gastroenterol* 1983; 78: 374-7.



12. Molleston JP, White F, Teckman J, Fitzgerald JF. Obese children with steatohepatitis can develop cirrhosis in childhood. *Am J Gastroenterol* 2002; 97: 2460-2.
13. Welsh JA, Karpen S, Vos MB. Increasing prevalence of non-alcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. *J Pediatr* 2013; 162: 496-500.
14. Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. *Hepatology* 2008; 48: 119-28.
15. Feldstein AE, Charatcharoenwittaya P, Treprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. *Gut* 2009; 58: 1538-44.
16. Grønbaek H, Lange A, Birkebaek NH, Holland-Fischer P, Solvig J, Hørlyck A, Kristensen K, et al. Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children. *J Pediatr Gastroenterol Nutr* 2012; 54: 223-8.
17. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. *Hepatology* 2010; 52: 79-104.
18. Bradford V, Dillon JF, Miller MH. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease. *Hepat Med* 2013; 14: 1-10.
19. Santomauro M, Valeri MP, Fernández M, Camacho N, Molina Z, Cicchetti R, Valeri L, et al. Non-alcoholic fatty liver disease and its association with clinical and biochemical variables in obese children and adolescents: effect of a one-year intervention on lifestyle. *Endocrinol Nutr* 2012; 59: 346-53.
20. Wang CL, Liang L, Fu JF, Zou CC, Hong F, Xue JZ, Lu JR, et al. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. *World J Gastroenterol* 2008; 14: 1598-602.
21. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. *J Hepatol* 2012; 57: 157-66.
22. Koot BGP, Slootweg OHB, Smeulders CLJT, Rijcken THP, Korevaar JC, van Aalderen WM, Jansen PLM, et al. Lifestyle intervention for non-alcoholic fatty liver disease: prospective cohort study of its efficacy and factors related to improvement. *Arch Dis Child* 2011; 96: 669-74.
23. Lee S, Bacha F, Hannon T, Kuk JL, Boesch C, Arslanian S. Effects of Aerobic Versus Resistance Exercise Without Caloric Restriction on Abdominal Fat, Intrahepatic Lipid, and Insulin Sensitivity in Obese Adolescent Boys A Randomized, Controlled Trial. *Diabetes* 2012; 61: 2787-2795.
24. Schwimmer JB. Clinical advances in pediatric nonalcoholic fatty liver disease. *Hepatology* 2016; 63: 1718-25.
25. Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the phenotype and approach to pediatric vs adult patients with nonalcoholic fatty liver disease. *Gastroenterology* 2016; 150: 1798-810.
26. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: International survey. *BMJ* 2000; 320: 1-6.
27. Van der Heijden GJ, Wang ZJ, Chu ZD, Sauer PJ, Haymond MW, Rodriguez LM, Sunehag AL. A 12-Week Aerobic Exercise Program Reduces Hepatic Fat Accumulation and Insulin Resistance in Obese, Hispanic Adolescents. *Obesity* 2010; 18: 384-90.
28. Antunes BDMM, Monteiro PA, Silveira LS, Cayres SU, Silva CBD, Júnior F, Forte I. Effect of concurrent training on risk factors and hepatic steatosis in obese adolescents. *Rev Paul Pediatr* 2013; 31: 371-6.
29. Tazawa Y, Noguchi H, Nishinomiya F, Takada G. Effect of weight changes on serum transaminase activities in obese children. *Acta Paediatr Jpn* 1997; 39: 210-14.
30. Tock L, Dâmaso AR, De Piano A, Carnier J, Sanches PL, Lederman HM, Ernandes RMY, et al. Long-term effects of metformin and lifestyle modification on nonalcoholic fatty liver disease obese adolescents. *J Obes* 2010.
31. Tock L, Prado WL, Caranti DA, Cristofalo DM, Lederman H, Fisberg M, Siqueira KO, et al. Nonalcoholic fatty liver disease decrease in obese adolescents after multidisciplinary therapy. *Eur J Gastroen Hepat* 2006; 18: 1241-1245.
32. Nadeau KJ, Ehlers LB, Zeitler PS, Love-Osborne K. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. *Pediatr Diabetes* 2009; 10: 5-13.
33. Farris JW, Taylor L, Williamson M, Robinson C. A 12-week interdisciplinary intervention program for children who are obese. *Cardiopulm Phys Ther J* 2011; 22: 12.
34. Reinehr T, Schmidt C, Toschke AM, Andler W. Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study. *Arch Dis Child* 2009; 94: 437-42.
35. Akcam M, Boyaci A, Pirgon O, Kaya S, Uysal S, Dundar BN. Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. *Int J Vitam Nutr Res* 2011; 81: 398-406.
36. Vajro P, Franzese A, Valerio G, Iannucci MP, Aragione N. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. *J Pediatr* 2000; 136: 739-43.
37. Verduci E, Pozzato C, Banderali G, Radaelli G, Arrizza C, Rovere A, Riva E, et al. Changes of liver fat content and transaminases in obese children after 12-mo nutritional intervention. *World J Hepatol* 2013; 5: 505-12.
38. Pozzato C, Verduci E, Scaglioni S, Radaelli G, Salvioni M, Rovere A, Cornalba G, et al. Liver fat change in obese children after a 1-year nutrition-behavior intervention. *J Pediatr Gastroenterol Nutr* 2010; 51: 331-5.
39. Nobili V, Marcellini M, Devito R, Ciampalini P, Piemonte F, Comparcola D, Sartorelli MR, et al. NAFLD in children: A prospective clinical-pathological study and effect of lifestyle advice. *Hepatology* 2006; 44: 458-65.
40. Brambilla P, Bedogni G, Heo M, Pietrobelli A. Waist circumference-to-height ratio predicts adiposity better than body mass index in children and adolescents. *Int J Obes* 2013; 37: 943-6.
41. Javed A, Jumean M, Murad MH, Okorodudu D, Kumar S, Somers VK, Sochor O, et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity in children and adolescents: a systematic review and meta-analysis. *Pediatr Obes* 2015; 10: 234-44.
42. Schwimmer JB, Newton KP, Awai HI, Choi LJ, Garcia MA, Ellis LL, Vanderwall K, et al. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected nonalcoholic fatty liver disease. *Aliment Pharmacol Ther* 2013; 38: 1267-77.
43. Awai HI, Newton KP, Sirlin CB, Behling C, Schwimmer JB. Evidence and recommendations for imaging liver fat in children, based on systematic review. *Clin Gastroenterol Hepatol* 2014; 12: 765-73.
44. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Björnsson ES, Charatcharoenwittaya P, Mills PR, et al. Liver fibrosis,

but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology* 2015; 149: 389-97.

45. Togashi K, Masuda H, Iguchi K. Effect of diet and exercise treatment for obese Japanese children on abdominal fat distribution. *Res Sports Med* 2010; 18: 62-70.

**Correspondence and reprint request:**

Melina Utz-Melere, M.D.  
572 Taquara Avenue 403,  
Porto Alegre - Rio Grande do Sul, Brasil.  
Tel.: +55 (51) 999173213. Fax.: +55(51) 33111457  
E-mail: mel\_melere@hotmail.com